After RBC Capital and H.C. Wainwright gave Provention Bio (NASDAQ: PRVB) a Buy rating last month, the company received another
Today, the EVP & CFO of McCormick & Company (MKC – Research Report), Michael R. Smith, bought shares of MKC
Today it was reported that a Director at TTM Technologies (TTMI – Research Report), Dov Zakheim, exercised options to sell
In a report released today, Kevin DeGeeter from Oppenheimer maintained a Buy rating on Moleculin Biotech (MBRX – Research Report),
In a report issued on June 30, Andy Hsieh from William Blair reiterated a Buy rating on Exelixis (EXEL –
In a report issued on June 29, Andy Hsieh from William Blair reiterated a Buy rating on Pfenex (PFNX –
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Bristol Myers
